"Our growth strategy to secure non-dilutive financingensured that we are well positioned to support current and additional new partnered programs inour pipeline without raising additional funds, as well as to continue to invest in proprietary R&Dprograms across a range of indications. The Company’s current financial position is strong, allowingus to continue building value for our shareholders through a pipeline of ddRNAi product candidatesin several chronic and life-threatening human diseases.”
No mention of oncology Hoyland. And those "additional new partnered programs" are positively mouth-watering? Alnylam, Arrowhead, Dicerna.....who could it be?
Ann: Appendix 4C - quarterly, page-4
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
